Why non-invasive brain stimulation matters in depression
Depression is not a homogeneous condition. Some profiles respond well to psychotherapy or pharmacotherapy; others — particularly in treatment-resistant depression (TRD) or with medical/psychiatric comorbidities — require additional strategies. Non-invasive brain stimulation (NIBS) does not replace comprehensive clinical management but can function as a response 'multiplier' when patient selection is appropriate, protocols are standardised and integration with standard treatment is ensured.
For families: if your relative has depression and standard treatments have not fully worked, this guide explains which brain stimulation techniques exist, when they may help and what to expect from the process.
What is non-invasive brain stimulation (rapid definitions)
Non-invasive brain stimulation (NIBS): techniques that modulate brain activity externally without surgery. In depression, two principal families are used: magnetic stimulation (rTMS and iTBS, variants of TMS) and transcranial electrical stimulation (tDCS, tACS and others such as tRNS). rTMS/iTBS targets networks implicated in depression (typically the dorsolateral prefrontal cortex, DLPFC); tDCS/tACS deliver low-intensity current via scalp electrodes.
For families: these are treatments that act on the brain from outside, without surgery or significant pain. They are delivered using specialised devices in sessions lasting minutes.
Available techniques and how they differ
- rTMS (repetitive transcranial magnetic stimulation): Primary indication: major depressive disorder, particularly with inadequate response to standard treatments (TRD). Clinical advantage: extensive evidence base and established clinical use. NICE describes typical protocols with daily sessions of approximately 30 minutes over 2–6 weeks. Practical limitation: requires daily attendance over several weeks.
- iTBS (intermittent theta burst stimulation): A condensed form of TMS with significantly shorter sessions (minutes) and comparable efficacy in specific contexts. A large non-inferiority trial supported its regulatory approval and widespread clinical adoption. Advantage: temporal efficiency enabling greater clinical scalability.
- tDCS (transcranial direct current stimulation): Low-intensity direct current delivered via scalp electrodes. Strengths: accessibility, lower cost, potential for supervised domiciliary protocols (per regulatory framework). Critical consideration: outcome heterogeneity — patient selection and treatment combination are determinant. The JAMA Network Open 2025 meta-analysis identified clearer signals for tDCS in depression with comorbidities (psychiatric or medical) and for tDCS combined with pharmacotherapy.
- tACS (transcranial alternating current stimulation): Alternating current aimed at modulating cerebral oscillatory rhythms. 2025 status: promising signals but evidence less consolidated than rTMS/iTBS and tDCS for some profiles. JAMA 2025 reported improvements in selected outcomes for MDD but underscored the need for confirmatory studies.
- HD-tDCS (high-definition tDCS): Electrical technique with enhanced focality (HD montages). A trial published in JAMA Network Open (2025) suggests clinical potential for personalised HD-tDCS as an antidepressant therapy (good tolerability, promising clinical outcomes).
2025–2026 clinical evidence: what can be stated today
- Strongest evidence (clinical practice): rTMS/iTBS: effective and safe treatment for depression, particularly in treatment-resistant profiles; iTBS offers a more time-efficient alternative where available and protocolised. tDCS: useful but heterogeneous evidence; JAMA 2025 suggests greater relative benefit in depression with comorbidities and in combination with pharmacotherapy.
- Promising but with greater uncertainty: tACS: improvement signals in selected outcomes, but robustness and protocol standardisation are lacking. HD-tDCS: clinical potential demonstrated in 2025 trial, pending replication.
Patient selection: the factor that determines success
- Typical candidates for rTMS/iTBS: Major depressive disorder with inadequate response to standard treatments (TRD). Patients who do not tolerate pharmacotherapy or prefer to reduce pharmacological burden (always under medical oversight). Patients requiring an intervention with robust evidence and structured follow-up.
- Typical candidates for tDCS/tACS: Mild-to-moderate depression where the protocol is validated and supervised. Profiles with comorbidities (psychiatric or medical) where JAMA 2025 observed benefit signals with tDCS. As adjunctive therapy to pharmacotherapy or psychotherapy (per clinical plan).
- When to exercise particular caution: Unstabilised bipolar disorder (activation risk). Active suicidal ideation (requires urgent management and safety planning; NIBS is not a first-line response). Epilepsy or elevated seizure risk (particularly relevant for TMS; although the risk is low, it must be protocolised).
Safety and adverse events: what patients need to know
- rTMS/iTBS: Common: scalp discomfort, headache, fatigue. Less common: dizziness, auditory discomfort (from device noise; hearing protection is used). Rare: seizure (low risk but documented; minimised through screening and protocol adherence). NICE describes structured clinical protocols and monitoring scales.
- tDCS/tACS: Common: tingling, skin erythema, mild headache. Serious risks: infrequent under standard conditions; tolerability is generally good in trials (including HD-tDCS).
Clinical protocols: what the patient can expect
- rTMS (typical protocol): Daily sessions (typically 5 days/week) over several weeks. NICE describes standard cycles of 2–6 weeks depending on protocol. Re-assessment using validated scales (MADRS/HDRS) and maintenance plan if response is achieved.
- iTBS: Significantly shorter sessions (minutes) enabling increased clinical throughput. In certain settings, accelerated protocols (multiple sessions per day) are being explored, with variable evidence and adoption.
- tDCS/tACS: Protocols vary (session number, electrode placement, current intensity). Montage/protocol consistency and profile selection are critical (heterogeneity explains many apparent 'contradictions' in outcome literature).
Integration with psychotherapy, pharmacotherapy and exercise (combined model)
- rTMS/iTBS + psychotherapy: Valuable for consolidating behavioural change when symptom burden decreases and the patient can 'do' more. Stimulation reduces symptomatic load; psychotherapy consolidates coping strategies.
- tDCS + pharmacotherapy: JAMA 2025 found an association with improvement when tDCS and pharmacotherapy are combined. Electrical stimulation potentiates pharmacological response in selected profiles.
- Exercise as co-treatment: Exercise has strong evidence as a depression treatment (BMJ 2024: walking, yoga, resistance training) and improves sleep, energy and global adherence to the therapeutic plan.
Evidence Sources
Fuentes
- JAMA Network Open 2025: meta-analysis of tDCS and tACS in depression — benefit signals in comorbidity profiles and pharmacotherapy combination
- NICE: rTMS protocols for depression, 2–6 week cycles with daily sessions
- 2024 clinical review: iTBS as an efficient, non-inferior alternative to standard high-frequency rTMS
- JAMA Network Open 2025: personalised HD-tDCS as a promising antidepressant therapy
- BMJ 2024 (Noetel et al.): exercise as effective depression treatment (network meta-analysis)
Request a multidisciplinary assessment (psychiatry/psychology + neuromodulation + therapeutic exercise) and a personalised protocol proposal by profile (treatment-resistant depression vs comorbidities) at GNeuro.